These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Structure-activity relationships of substituted oxyoxalamides as inhibitors of the human soluble epoxide hydrolase. Kim IH; Lee IH; Nishiwaki H; Hammock BD; Nishi K Bioorg Med Chem; 2014 Feb; 22(3):1163-75. PubMed ID: 24433964 [TBL] [Abstract][Full Text] [Related]
7. Three-dimensional rational approach to the discovery of potent substituted cyclopropyl urea soluble epoxide hydrolase inhibitors. Takai K; Chiyo N; Nakajima T; Nariai T; Ishikawa C; Nakatani S; Ikeno A; Yamamoto S; Sone T Bioorg Med Chem Lett; 2015 Apr; 25(8):1705-1708. PubMed ID: 25800114 [TBL] [Abstract][Full Text] [Related]
9. Exploring the size of the lipophilic unit of the soluble epoxide hydrolase inhibitors. Codony S; Valverde E; Leiva R; Brea J; Isabel Loza M; Morisseau C; Hammock BD; Vázquez S Bioorg Med Chem; 2019 Oct; 27(20):115078. PubMed ID: 31488357 [TBL] [Abstract][Full Text] [Related]
10. Discovery and Optimization of Piperazine Urea Derivatives as Soluble Epoxide Hydrolase (sEH) Inhibitors. Çapan İ; Jordan PM; Olğaç A; Çalışkan B; Kretzer C; Werz O; Banoglu E ChemMedChem; 2022 Jun; 17(12):e202200137. PubMed ID: 35466565 [TBL] [Abstract][Full Text] [Related]
11. Discovery of benzamide derivatives containing urea moiety as soluble epoxide hydrolase inhibitors. Tian Y; Li S; Dong K; Su X; Fu S; Lv X; Duan M; Yang T; Han Y; Hu G; Liu J; Sun Y; Yue H; Sun Y; Zhang H; Du Z; Miao Z; Tong M; Liu Y; Qin M; Gong P; Hou Y; Gao Z; Zhao Y Bioorg Chem; 2022 Oct; 127():105898. PubMed ID: 35792317 [TBL] [Abstract][Full Text] [Related]
12. Structure-based optimization of cyclopropyl urea derivatives as potent soluble epoxide hydrolase inhibitors for potential decrease of renal injury without hypotensive action. Takai K; Nakajima T; Takanashi Y; Sone T; Nariai T; Chiyo N; Nakatani S; Ishikawa C; Yamaguchi N; Fujita K; Yamada K Bioorg Med Chem; 2014 Mar; 22(5):1548-57. PubMed ID: 24530032 [TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and evaluation of non-urea inhibitors of soluble epoxide hydrolase. Pecic S; Deng SX; Morisseau C; Hammock BD; Landry DW Bioorg Med Chem Lett; 2012 Jan; 22(1):601-5. PubMed ID: 22079754 [TBL] [Abstract][Full Text] [Related]
14. Solid-phase combinatorial approach for the optimization of soluble epoxide hydrolase inhibitors. Hwang SH; Morisseau C; Do Z; Hammock BD Bioorg Med Chem Lett; 2006 Nov; 16(22):5773-7. PubMed ID: 16949285 [TBL] [Abstract][Full Text] [Related]
16. Optimization of amide-based inhibitors of soluble epoxide hydrolase with improved water solubility. Kim IH; Heirtzler FR; Morisseau C; Nishi K; Tsai HJ; Hammock BD J Med Chem; 2005 May; 48(10):3621-9. PubMed ID: 15887969 [TBL] [Abstract][Full Text] [Related]
17. Pharmacophoric modeling and atom-based 3D-QSAR of novel 1-aryl-3-(1-acylpiperidin-4-yl) urea as human soluble epoxide hydrolase inhibitors (sEHIs). Das N; Dhanawat M; Kulshrestha A; Shrivastava SK Med Chem; 2011 Nov; 7(6):581-92. PubMed ID: 22313298 [TBL] [Abstract][Full Text] [Related]